Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

KYTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Kyverna Therapeutics, Inc.NASDAQ: KYTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$351K, compared with -$501K a year earlier. Trailing-twelve-month gross profit was -$866K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$351K or moves back toward the trailing-twelve-month quarterly average of -$216.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$351K— QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
-$866K+97.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.9%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Gross Profit vs competitors

How KYTX compares with its peers on the latest reported figures

  • KYTX's LTM Mar 2026 gross profit of -$866K is the 7th highest of the 11 companies compared; the peer median is -$537.32K.
  • Its year-over-year change of +97.1% is the 2nd highest of 7, against a peer median of +9.5%.
KYTX Competitors Peer median
Gross Profit for KYTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EDITEditas Medicine, Inc.LTM Mar 2026$2.25M +105.3%+44.7%5.8%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K —-62.8%66.4%
CABACabaletta Bio, Inc.LTM Mar 2026$0 ———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$79K ———
MREOMereo BioPharma Group plcLTM Mar 2026-$528.63K +51.3%+12.5%105.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$546K ———
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$866K +97.1%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$2.3M -3640.0%—7422.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M -72.9%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$42.41M -4.9%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M +23.8%——
Peer median (excluding KYTX) -$537.32K+9.5%+12.5%86.1%

Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.66M7.03M000
Cost of Revenue001.71M2.13M0
Gross Profit5.66M7.03M(1.71M)(2.13M)0
Gross Margin100.0%100.0%———
Research & Development25.85M28.4M48.22M112.47M133.72M
Selling, General & Admin6.15M8.01M12.48M30.13M36.11M
Operating Expenses32M36.41M60.7M140.47M169.83M
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
EBITDA(25.76M)(27.78M)(58.47M)(125.2M)(159.02M)
EBITDA Margin-455.5%-395.4%———
Operating Income(26.35M)(29.38M)(62.41M)(142.6M)(169.83M)
Operating Margin-465.8%-418.3%———
Interest Income1K565K2.28M15.36M9.09M
Interest Expense3K65K187K142K489K
Other Income / Expenses(4K)491K2.04M15.13M8.52M
Income Before Tax(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Pre-Tax Margin-465.9%-411.3%———
Income Tax Expense00000
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Net Margin-465.9%-411.3%———
EPS (Basic)(1.02)(1.12)(0.00)(3.33)(3.64)
EPS (Diluted)(1.02)(1.12)(0.00)(3.33)(3.64)
Weighted Avg Shares25.8M25.8M673.62M38.33M44.26M
Weighted Avg Shares (Diluted)25.8M25.8M673.62M38.33M44.26M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Intrinsic Alpha fair value

Locked

Current Price

$4.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.